Infex RESP-X shows safety, reduces exacerbations in bronchiectasis trial
Infex RESP-X shows safety, reduces exacerbations in bronchiectasis trial. Quarterly dosing monoclonal targets pseudomonas virulence.
TaiMed Biologics Completes Phase 2b Enrollment for TMB-365/380 HIV Therapy
TaiMed Biologics completes Phase 2b enrollment for TMB-365/380 HIV therapy, a dual antibody combination dosed every two months without...
Nuvalent to Present Neladalkib and Zidesamtinib Data at 2026 ASCO
Nuvalent neladalkib achieves oral presentation at 2026 ASCO for ALK-positive NSCLC, with NDA filed in April ahead of FDA...
Sapience’s lucicebtide shows 28.4-month median survival in glioblastoma Phase 2
Sapience's lucicebtide demonstrated 28.4-month median progression-free survival in newly diagnosed glioblastoma, significantly exceeding historical benchmarks i
Tedopi Plus Pembrolizumab Extends Survival in Recurrent Ovarian Cancer
Tedopi Plus Pembrolizumab extends median PFS to 4.1 months in platinum-sensitive recurrent ovarian cancer, marking the first positive randomized...
BIIB122 fails to slow motor decline in early Parkinson’s disease trial
BIIB122 fails to slow motor decline in early Parkinson's disease trial despite strong target engagement and biomarker effects.
Achieve Life Sciences Presents 52-Week Safety Data for Cytisinicline
Achieve Life Sciences presents 52-week safety data for cytisinicline ahead of June 2026 FDA decision, showing low nausea rates...
Quince’s LAM-001 Shows Functional Gains in Phase 2a PH-ILD Study
LAM-001 Phase 2a study shows 67-meter walk distance gain and improved functional class in PH-ILD patients on background treprostinil...
Alterity’s ATH434 Shows 48% Slowing of Decline in MSA Phase 2 Trial
ATH434 shows 48% slowing of functional decline in MSA Phase 2 trial, with significant improvements in swallowing and iron...
Infex Therapeutics’ RESP-X shows exploratory efficacy signal in Phase IIa bronchiectasis study
RESP-X Phase IIa shows exploratory efficacy signal in bronchiectasis study, with quarterly dosing potential and clean safety profile across...